Literature DB >> 2890391

Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine.

G B Baker1, R T Coutts, T S Rao.   

Abstract

1 N-(2-cyanoethyl)-2-phenylethylamine (CEPEA) was examined as a possible prodrug of 2-phenylethylamine (PEA). 2 Pharmacokinetics of PEA and CEPEA were investigated in rat brain, blood and liver by gas chromatography with electron-capture detection (GC-ECD). Interactions of PEA and CEPEA with putative neurotransmitter amines were investigated by use of high performance liquid chromatography with electrochemical detection (h.p.l.c.-e.c.). 3 Administration of PEA caused transient increases in PEA concentrations which decreased rapidly in brain and blood and at a slower rate in liver. Administration of CEPEA caused sustained elevations of PEA concentrations and elimination of PEA was markedly decreased in these tissues relative to the situation after administration of PEA itself. 4 Administration of CEPEA caused more prolonged decreases in brain noradrenaline, dopamine and 5-hydroxytryptamine concentrations than those observed after PEA administration, although values increased to control levels eventually.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890391      PMCID: PMC1853650          DOI: 10.1111/j.1476-5381.1987.tb11318.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Electron-capture gas chromatographic analysis of beta-phenylethylamine in tissues and body fluids using pentafluorobenzenesulfonyl chloride for derivatization.

Authors:  G B Baker; T S Rao; R T Coutts
Journal:  J Chromatogr       Date:  1986-09-05

2.  Non-selective inhibition of GABA and 5-HT uptake systems in rat brain by N-n-alkyl hydroxybenzylamine and N-n-alkyl phenylethylamine derivatives.

Authors:  C J Suckling; R J Breckenridge; S S Bansal; L C Williams; K J Watling; L L Iversen
Journal:  Biochem Pharmacol       Date:  1985-12-01       Impact factor: 5.858

3.  The behavioural effects of phenelzine and phenylethylamine may be due to amine release.

Authors:  L E Dyck
Journal:  Brain Res Bull       Date:  1984-01       Impact factor: 4.077

4.  In vivo release of endogenous dopamine from rat caudate nucleus by phenylethylamine.

Authors:  S R Philips; A M Robson
Journal:  Neuropharmacology       Date:  1983-11       Impact factor: 5.250

5.  The effects of beta-phenylethylamine on tyramine and dopamine metabolism.

Authors:  P S McQuade; P L Wood
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1983       Impact factor: 5.067

6.  Effects of alpha-carbon substituents on the N-demethylation of N-methyl-2-phenethylamines by rat liver microsomes.

Authors:  J D Duncan; G Hallström; U Paulsen-Sörman; B Lindeke; A K Cho
Journal:  Drug Metab Dispos       Date:  1983 Jan-Feb       Impact factor: 3.922

7.  Inhibition of locus coeruleus neuronal activity by beta-phenylethylamine.

Authors:  P A Lundberg; L Oreland; G Engberg
Journal:  Life Sci       Date:  1985-05-13       Impact factor: 5.037

Review 8.  Phenylethylamine in neuropsychiatric disorders.

Authors:  M E Wolf; A D Mosnaim
Journal:  Gen Pharmacol       Date:  1983

9.  Metabolism and disposition of N-(2-cyanoethyl)amphetamine (fenproporex) and amphetamine: study in the rat brain.

Authors:  R T Coutts; A J Nazarali; G B Baker; F M Pasutto
Journal:  Can J Physiol Pharmacol       Date:  1986-06       Impact factor: 2.273

10.  [14C]-beta-phenethylamine, its distribution after administration by various routes to cats, and the effects of monoamine oxidase inhibitors.

Authors:  G Garcha; P R Imrie; E Marley; D V Thomas
Journal:  Br J Pharmacol       Date:  1985-12       Impact factor: 8.739

View more
  12 in total

1.  Effect of noradrenergic system on the anxiolytic-like effect of DOI (5-HT2A/2C agonists) in the four-plate test.

Authors:  Fabienne Massé; Martine Hascoët; Eric Dailly; Michel Bourin
Journal:  Psychopharmacology (Berl)       Date:  2005-11-24       Impact factor: 4.530

2.  Chronic treatment with D1 and D2 dopamine receptor agonists: combined treatments interact to differentially affect brain levels of monoamines.

Authors:  M T Martin-Iverson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-09       Impact factor: 3.000

3.  "Designer" amphetamines: effects on behavior and monoamines with or without reserpine and/or alpha-methyl-para-tyrosine pretreatment.

Authors:  M T Martin-Iverson; N Yamada; A W By; B A Lodge
Journal:  J Psychiatry Neurosci       Date:  1991-12       Impact factor: 6.186

4.  Pharmacokinetic and neurochemical studies on N-propargyl-2-phenylethylamine, a prodrug of 2-phenylethylamine.

Authors:  T S Rao; G B Baker; R T Coutts
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

5.  Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.

Authors:  K M Hegadoren; M T Martin-Iverson; G B Baker
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

6.  N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines.

Authors:  K F McKenna; G B Baker; R T Coutts
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

7.  Inhibition of rat brain monoamine oxidase enzymes by fluoxetine and norfluoxetine.

Authors:  A Holt; G B Baker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

8.  Comparison of phenelzine and geometric isomers of its active metabolite, β-phenylethylidenehydrazine, on rat brain levels of amino acids, biogenic amine neurotransmitters and methylamine.

Authors:  Dmitriy Matveychuk; Emerson Nunes; Nasir Ullah; Carlos A Velázquez-Martinez; Erin M MacKenzie; Glen B Baker
Journal:  J Neural Transm (Vienna)       Date:  2013-02-08       Impact factor: 3.575

9.  Synthesis, transport, and metabolism of serotonin formed from exogenously applied 5-HTP after spinal cord injury in rats.

Authors:  Yaqing Li; Lisa Li; Marilee J Stephens; Dwight Zenner; Katherine C Murray; Ian R Winship; Romana Vavrek; Glen B Baker; Karim Fouad; David J Bennett
Journal:  J Neurophysiol       Date:  2013-09-25       Impact factor: 2.714

Review 10.  2-Phenylethylamine-induced changes in catecholamine receptor density: implications for antidepressant drug action.

Authors:  P R Paetsch; A J Greenshaw
Journal:  Neurochem Res       Date:  1993-09       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.